Cytek Biosciences, Inc.
CTKB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001831915
No open-market purchases or sales by Cytek Biosciences, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $361.0M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Superinvestors holding CTKB, Q2 2026
1 superinvestor reports holding Cytek Biosciences, Inc. on Form 13F, worth $29.5M in total. Weight is Cytek Biosciences, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| HHLR Advisors (Hillhouse)Zhang Lei | 3.5% | 6,657,030 | $29.5M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of CTKB each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2023
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−13.6%)
Q1 2023
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−11.3%)
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−0.8%)
Q3 2021
1 superinvestor holding at quarter end